share_log

Bellerophon Therapeutics Shares Are Trading Higher After the FDA Accepted the Company's Proposal to Reduce the Study Size for Its Ongoing Registrational REBUILD Phase 3 Trial of INOpulse for the Treatment of Fibrotic Interstitial Lung Disease.

Bellerophon Therapeutics Shares Are Trading Higher After the FDA Accepted the Company's Proposal to Reduce the Study Size for Its Ongoing Registrational REBUILD Phase 3 Trial of INOpulse for the Treatment of Fibrotic Interstitial Lung Disease.

在FDA接受了該公司正在進行的INOPulse治療間質性肺疾病註冊重建第三階段試驗的研究規模的建議後,Bellerophon治療公司的股價上漲。
Benzinga ·  2022/09/27 15:31

Bellerophon Therapeutics shares are trading higher after the FDA accepted the company's proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse for the treatment of fibrotic Interstitial Lung Disease.

在FDA接受了該公司的提議,縮小其正在進行的INOPulse治療纖維化間質性肺部疾病的註冊重建第三階段試驗的研究規模後,Bellerophon治療公司的股價上漲。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論